Wired reported significant scientific criticism of the project’s claims and methods; Bruce Walker and David Heckerman distanced themselves from the work, and critics argued the public messaging overstated the science.
SourcePublic company, workplace, funding, and market signals
Updated Jul 29, 2026
Immunity Project is a mission-driven nonprofit focused on developing a free HIV vaccine by using machine learning and immunology research to identify HIV targets from natural HIV controllers.
Primary product
A synthetic/free HIV vaccine intended for global distribution
Founded
2013
Headquarters
Oakland, California, United States
Team size
1-10
Industry
Wellness and Fitness Services
Sub-industry
Biotechnology / HIV vaccine R&D
Offices
0 jobs at Immunity Project
Check back later for new openings
Business model
Investors
Mission-driven, scientific nonprofit culture centered on open-ended vaccine R&D, crowdfunding, and a promise of free global access if the vaccine succeeds.
Pricing
Free to end users; research and development funded through donations, crowdfunding, grants, and partner backing.
Differentiators
Technology
Competitors
Wired reported significant scientific criticism of the project’s claims and methods; Bruce Walker and David Heckerman distanced themselves from the work, and critics argued the public messaging overstated the science.
SourceCoverage around the launch emphasized that the project still needed substantial funding for Phase 1 trials, underscoring execution and financing risk.
SourceBlab Tech · Jun 2026
A 2026 retrospective describing Immunity Project as an early machine-learning-driven HIV vaccine effort backed by Y Combinator and focused on free global distribution.
WIRED · Feb 2014
Critical reporting that questioned the project’s scientific claims, highlighted advisor attribution disputes, and emphasized the scientific and execution risk.
Fast Company · Jan 2014
Launch coverage describing the synthetic HIV vaccine concept, the free-to-users model, and the roles of Reid Rubsamen, Bruce Walker, and David Heckerman.
VentureBeat · Jan 2014
Coverage of the Y Combinator acceptance, machine-learning approach, and a crowdfunding push for final blood experiments.
The Verge · Jan 2014
Explains the crowdfunding target, the hoped-for timeline, and the large funding needs for Phase 1 clinical trials.